<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595618</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG1972-CL-201</org_study_id>
    <secondary_id>2017-004581-10</secondary_id>
    <nct_id>NCT03595618</nct_id>
  </id_info>
  <brief_title>A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Patients With Knee Osteoarthritis</brief_title>
  <acronym>Roccella</acronym>
  <official_title>Efficacy and Safety of 3 Doses of S201086/GLPG1972 Administered Orally Once Daily in Patients With Knee Osteoarthritis. A 52-week International, Multi-regional, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2, 52-week international, multi-regional, multicenter, randomized,
      double-blind, placebo-controlled dose-ranging study for the treatment of Osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">July 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cartilage thickness of the central medial tibiofemoral compartment (cMTFC) assessed by quantitative MRI on the target knee.</measure>
    <time_frame>Between Week 0 and Week 52</time_frame>
    <description>To demonstrate the efficacy of at least one dose (among 3 doses) of S201086/GLPG1972 compared to placebo in reducing cartilage loss measured by cartilage thickness of the cMTFC of the target knee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of osteoarthritis (OA) structural progressors based on cartilage thickness in the central medial tibiofemoral compartment (cMTFC) assessed by quantitative MRI on the target knee.</measure>
    <time_frame>52 weeks</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks of treatment on the proportion of structural progressors based on cartilage thickness in the CMTFC assessed of the target knee. A structural progressor is defined as a patient who had at least 8% cartilage loss in the cMTFC between baseline and Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales scores for pain, function, and stiffness.</measure>
    <time_frame>Between Week 0 and Week 52</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks on iso of pain, function, and stiffness measured with WOMAC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pain in the target knee measured with a 100-mm visual analog scale (VAS).</measure>
    <time_frame>Between Week 0 and Week 52</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks of treatment on pain measured with a 100-mm visual analog scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient global assessment (PGA) of disease activity measured with 100-mm visual analog scale (VAS).</measure>
    <time_frame>Between Week 0 and Week 52</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks of treatment on patient PGA of disease activity measured with 100-mm VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI) responders.</measure>
    <time_frame>Week 52</time_frame>
    <description>Based on OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for OA clinical trials revisited Pham et al. 2004. A responder is defined according to WOMAC and PGA as a patient who had a high improvement in pain or in function ≥ 50% and absolute change ≥ 20 or, improvement in at least 2 of the 3 following:
Pain ≥ 20% and absolute change ≥ 10
Function ≥ 20% and absolute change ≥ 10
Patient's global assessment ≥ 20% and absolute change ≥ 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cartilage thickness of the total tibiofemoral compartment (tTFC) of the target knee by quantitative MRI.</measure>
    <time_frame>Between Week 0 and Week 52.</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks of treatment on reduction of cartilage loss measured by cartilage thickness using quantitative MRI of the total tibiofemoral compartment (tTFC) of the target knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone area of the medial femoral condyle surface of the target knee by quantitative MRI.</measure>
    <time_frame>Between Week 0 and Week 28</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo on the bone area of the target knee using quantitative MRI of the medial femoral condyle surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone area of the medial femoral condyle surface of the target knee by quantitative MRI.</measure>
    <time_frame>Between Week 0 and Week 52</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo on the bone area of the target knee using quantitative MRI of the medial femoral condyle surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in Joint Space Width (JSW) of the target knee measured by X-Ray.</measure>
    <time_frame>Between Week 0 and Week 52.</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks of treatment on the target knee using X-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain: analgesic consumption throughout the study.</measure>
    <time_frame>Between Week 0 and Week 52.</time_frame>
    <description>To assess efficacy of 3 doses of S201086/GLPG1972 versus placebo after 52 weeks of treatment on analgesic consumption.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">938</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>GLPG1972 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A daily dose of 1 film-coated tablet of GLPG1972 for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG1972 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A daily dose of 2 film-coated tablets of GLPG1972 for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG1972 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A daily dose of 4 film-coated tablets of GLPG1972 for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A daily dose of film-coated tablets for oral use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG1972</intervention_name>
    <description>Film-coated tablets of GLPG1972 for oral use.</description>
    <arm_group_label>GLPG1972 Dose A</arm_group_label>
    <arm_group_label>GLPG1972 Dose B</arm_group_label>
    <arm_group_label>GLPG1972 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablets of matching placebo for oral use.</description>
    <arm_group_label>GLPG1972 Dose A</arm_group_label>
    <arm_group_label>GLPG1972 Dose B</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients or female patients of non-childbearing potential Age between 40 to 75
             years (both inclusive).

          -  Body weight &gt; 40 kg, body mass index (BMI) &lt; 40 kg/m2.

          -  Diagnosed for knee osteoarthritis based on clinical and radiological criteria of the
             American College of Rheumatology.

          -  History of knee pain for at least 6 months and on the majority of days (&gt; 50%) during
             the preceding month.

          -  Symptom severity defined by a pain ≥ 40 mm and ≤ 90 mm on VAS (100 mm).

          -  Documented need for symptomatic as needed-treatment for OA in the target knee with
             systemic non-steroidal anti-inflammatory drugs (NSAIDs) and/or other analgesics

        Exclusion Criteria:

          -  Severe clinical knee malalignment according to the investigator.

          -  Knee prosthesis already implanted (&lt; 1 year) or not well-tolerated (contralateral
             side).

          -  Knee prosthesis already foreseen within the study period (whichever side)

          -  Hip prosthesis recently implanted (&lt; 1 year) or foreseen within the study period
             (whichever side).

          -  Previous osteotomy on the inferior limbs (whichever side).

          -  Surgical operation on the target knee within the 12 months prior to the screening
             visit or planned during the study.

          -  Arthroscopy of the target knee within the 6 months prior to the screening visit or
             planned during the study.

          -  Other pathologies affecting the knee.

          -  Any contraindication to MRI including the inability to undergo a knee MRI exam because
             of inability to fit in the scanner or knee coil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri Deckx</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Research Associates, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute, LLC - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Arizona</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samy Metyas MD, Inc - Covina Arthritis Clinic</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioSolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Helm Center for Pain Management</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research - San Marcos</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Musculoskeletal Care - Yale Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates Clinical Study Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Injury Care Research, LLC</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center - Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Reasearch</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LCC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LTD</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center, LCC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc. - Newport News</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

